Latest stories on LABT
Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers
PR Newswire61 · neutralproduct/pr
Lakewood-Amedex’s Nu-3 Achieves Key Milestones Ahead of Phase 2 Trials for Diabetic Foot Ulcers
MarketChameleon67 · bullishproduct/pr
Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3
PR Newswire58 · neutralproduct/pr